Literature DB >> 15821401

Panel of prototypical infectious molecular HIV-1 clones containing multiple nucleoside reverse transcriptase inhibitor resistance mutations.

Elizabeth Johnston1, Kathryn M Dupnik, Matthew J Gonzales, Mark A Winters, Soo-Yon Rhee, Tomozumi Imamichi, Robert W Shafer.   

Abstract

We have created a panel of recombinant HIV-1 infectious clones containing common patterns of reverse transcriptase (RT) mutations responsible for resistance to each of the currently available nucleoside reverse transcriptase inhibitors (NRTI), and we have submitted the panel to the National Institutes of Health AIDS Research and Reference Reagent Programme. Testing the activity of new antiretroviral compounds against this panel of drug-resistant clones will determine their relative activity against many clinically relevant NRTI-resistant viruses.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15821401      PMCID： PMC2573397          DOI： 10.1097/01.aids.0000166098.54564.0c

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  12 in total

1.  Protease and reverse transcriptase mutation patterns in HIV type 1 isolates from heavily treated persons: comparison of isolates from Northern California with isolates from other regions.

Authors:  Matthew J Gonzales; Ilana Belitskaya; Kathryn M Dupnik; Soo-Yon Rhee; Robert W Shafer
Journal:  AIDS Res Hum Retroviruses       Date:  2003-10       Impact factor: 2.205

2.  Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates.

Authors:  Jeannette M Whitcomb; Neil T Parkin; Colombe Chappey; Nicholas S Hellmann; Christos J Petropoulos
Journal:  J Infect Dis       Date:  2003-09-16       Impact factor: 5.226

3.  Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors.

Authors:  Matthew J Gonzales; Thomas D Wu; Jonathan Taylor; Ilana Belitskaya; Rami Kantor; Dennis Israelski; Sunwen Chou; Andrew R Zolopa; W Jeffrey Fessel; Robert W Shafer
Journal:  AIDS       Date:  2003-04-11       Impact factor: 4.177

4.  Relative replication fitness of a high-level 3'-azido-3'-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr-->Gly) at codon 69.

Authors:  T Imamichi; S C Berg; H Imamichi; J C Lopez; J A Metcalf; J Falloon; H C Lane
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

Review 5.  Genotypic testing for human immunodeficiency virus type 1 drug resistance.

Authors:  Robert W Shafer
Journal:  Clin Microbiol Rev       Date:  2002-04       Impact factor: 26.132

6.  Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients.

Authors:  Michael D Miller; Nicolas Margot; Biao Lu; Lijie Zhong; Shan-Shan Chen; Andrew Cheng; Michael Wulfsohn
Journal:  J Infect Dis       Date:  2004-02-10       Impact factor: 5.226

7.  Distribution of human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns in 4,183 persons undergoing genotypic resistance testing.

Authors:  Soo-Yon Rhee; Tommy Liu; Jaideep Ravela; Matthew J Gonzales; Robert W Shafer
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

Review 8.  Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance.

Authors:  Joel E Gallant; Peter Z Gerondelis; Mark A Wainberg; Nancy S Shulman; Richard H Haubrich; Marty St Clair; Ernest R Lanier; Nicholas S Hellmann; Douglas D Richman
Journal:  Antivir Ther       Date:  2003-12

9.  K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine.

Authors:  Birgit T Røge; Terese L Katzenstein; Niels Obel; Henrik Nielsen; Ole Kirk; Court Pedersen; Lars Mathiesen; Jens Lundgren; Jan Gerstoft
Journal:  Antivir Ther       Date:  2003-04

10.  Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients.

Authors:  Nancy S Shulman; Michael D Hughes; Mark A Winters; Robert W Shafer; Andrew R Zolopa; Nicholas S Hellmann; Michael Bates; Jeannette M Whitcomb; David A Katzenstein
Journal:  J Acquir Immune Defic Syndr       Date:  2002-10-01       Impact factor: 3.731
View more
  14 in total

1.  Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine.

Authors:  Maya Balamane; Vici Varghese; George L Melikian; W Jeffrey Fessel; David A Katzenstein; Robert W Shafer
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

Review 2.  Drug resistance and antiretroviral drug development.

Authors:  Robert W Shafer; Jonathan M Schapiro
Journal:  J Antimicrob Chemother       Date:  2005-04-21       Impact factor: 5.790

3.  Exploiting the anti-HIV-1 activity of acyclovir: suppression of primary and drug-resistant HIV isolates and potentiation of the activity by ribavirin.

Authors:  Christophe Vanpouille; Andrea Lisco; Andrea Introini; Jean-Charles Grivel; Arshi Munawwar; Melanie Merbah; Raymond F Schinazi; Marco Derudas; Christopher McGuigan; Jan Balzarini; Leonid Margolis
Journal:  Antimicrob Agents Chemother       Date:  2012-02-06       Impact factor: 5.191

4.  Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog-Associated Mutations and M184V.

Authors:  Nicolas Margot; Renee Ram; Michael Abram; Richard Haubrich; Christian Callebaut
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

5.  Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Zhijun Zhang; Michelle Walker; Wen Xu; Jae Hoon Shim; Jean-Luc Girardet; Robert K Hamatake; Zhi Hong
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

6.  Agreement between an in-house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to HIV-1 protease, reverse transcriptase, and integrase inhibitors.

Authors:  Francesco Saladini; Alessia Giannini; Adele Boccuto; Ilaria Vicenti; Maurizio Zazzi
Journal:  J Clin Lab Anal       Date:  2017-03-17       Impact factor: 2.352

7.  Indirubin 3'-monoxime, from a Chinese traditional herbal formula, suppresses viremia in humanized mice infected with multidrug-resistant HIV.

Authors:  Alonso Heredia; Senthilkumar Natesan; Nhut M Le; Sandra Medina-Moreno; Juan C Zapata; Marvin Reitz; Joseph Bryant; Robert R Redfield
Journal:  AIDS Res Hum Retroviruses       Date:  2014-02-07       Impact factor: 2.205

8.  Characterization of HIV-1 Resistance to Tenofovir Alafenamide In Vitro.

Authors:  Nicolas A Margot; Audun Johnson; Michael D Miller; Christian Callebaut
Journal:  Antimicrob Agents Chemother       Date:  2015-07-06       Impact factor: 5.191

9.  A common anti-cytomegalovirus drug, ganciclovir, inhibits HIV-1 replication in human tissues ex vivo.

Authors:  Christophe Vanpouille; Jean A Bernatchez; Andrea Lisco; Anush Arakelyan; Elisa Saba; Matthias Götte; Leonid Margolis
Journal:  AIDS       Date:  2017-07-17       Impact factor: 4.177

10.  Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.

Authors:  Vici Varghese; Yumi Mitsuya; Rajin Shahriar; Michael H Bachmann; W Jeffrey Fessel; Ron M Kagan; Robert W Shafer
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.